DNA Payments Launches POS Alipay+ Acceptance for over 50,000 UK Merchants
UK merchants using DNA Payments’ POS have started to accept direct payments from 14 e-wallets…
2 years ago
Wire Stories
Another “Maritime Heavyweight” Added! JSD6000 Deepwater Lifting and Pipe-Laying Vessel Successfully Completed
SHANGHAI--(BUSINESS WIRE)--On May 28, the completion ceremony of the JSD6000 deepwater lift pipelay vessel project…
2 years ago
“MOURI Tech†Expands Global Footprint with Acquisition of “Versant Systemsâ€, Strengthening Presence in APAC Region
DALLAS--(BUSINESS WIRE)--#Acquisition--MOURI Tech LLC, a global enterprise IT services provider, announced the acquisition of Versant…
2 years ago
Appointment of Director to Woodside Board
PERTH, Australia--(BUSINESS WIRE)--The Woodside Board is pleased to announce the appointment of Mr Anthony (Tony)…
2 years ago
Nissan Demonstrates Autonomous-Drive Mobility Services Progress on Public Roads
YOKOHAMA, Japan--(BUSINESS WIRE)--Nissan has commenced demonstrations of a prototype vehicle equipped with its in-house-developed, autonomous…
2 years ago
Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
Exciting New Application from Intel Enables Fast PC-to-PC Connectivity TAIPEI, Taiwan--(BUSINESS WIRE)--#Intel--Other World Computing –…
2 years ago
Stronger Than Ever: Adani Portfolio Delivers Record Performance
45% EBITDA growth in FY24, EBITDA reaches USD 10 Bn Adani Portfolio EBITDA increased to…
2 years ago
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
Integration enhances the Denodo Platform, providing enterprise customers with faster, more secure, and fully scalable…
2 years ago
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
At the office opening today, Ãngel Viña, CEO of Denodo will be joined by Dr.…
2 years ago
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca’s ENHERTU is the first HER2 directed medicine and…
2 years ago